Abstract:e20127 Background: Immune checkpoint inhibitors (ICIs) combined with etoposide and platinum-based chemotherapy improves prognosis of patients with extensive-stage small-cell lung cancer (ES-SCLC). However, nearly 40% of patients do not benefit from Immunochemotherapy. Herein, this phase II study of first-line immunochemotherapy was conducted aiming to investigate potential biomarkers associated with therapeutic efficacy. Methods: A multi-center, single-arm, prospective phase II trial (ChiCTR2000038354) was designed and conducted to evaluate the efficacy and safety of sintilimab combined with platinum-based chemotherapy in patients with ES-SCLC who had not previously received treatment. The primary endpoint of this study is progression-free survival (PFS), with patients being defined as disease progression according to RECIST 1.1. Pre-treatment FFPE samples were analyzed using whole exome sequencing (WES) and whole transcriptome sequencing (WTS) to investigate biomarkers. Results: A total of 44 patients were included in the study, with a median follow-up of 10 months and a median PFS of 7.57 months. 8 patients with a PFS greater than 6 months were defined as the responder group (R group) and 5 patients with a PFS less than 6 months belonged to the non-responder group (NR group). WES and WTS were performed on the pre-treatment samples of these 13 patients. WES results revealed mutation frequencies of TP53 (69%), RB1 (31%) and FAT1 (31%) aligning with prior research. Significantly, ZFHX4 mutations correlated with R group (p = 0.05). Genomic instability, as defined by Homologous Recombination Deficiency (HRD) scores, displayed higher scores in NR group than in R group (p = 0.023), which suggests potential benefits of PARP inhibition in the NR group. WTS data revealed that higher M2/M1 macrophage ratio (p = 0.028) in NR group. Additionally, the NR group demonstrated significant VEGFA overexpression. Besides, NOTCH-signaling (p = 0.034), KRAS-signaling-DN (p<0.001), Angiogenesis (p<0.001) and EMT (p<0.001) pathway were also enriched in NR group. Conversely, M1 macrophages (p = 0.079), CD4+T cells (p = 0.093), Mast cells (p = 0.045), NK cells (p = 0.045) and neutrophils (p = 0.06) was higher in R group. Conclusions: This study highlights genomic instability as well as activation of cancer hallmarks such as angiogenesis, EMT may result the resistance to immunotherapy in ES-SCLC patients. These findings may shed light on combinational strategy overcoming therapeutic resistance. Clinical trial information: ChiCTR2000038354.

Advances in biomarkers for immunotherapy in small-cell lung cancer

The advances in immunotherapy biomarkers of small cell lung cancer

Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer

Treatment of Small Cell Lung Cancer: Recent Advances

The Progress of PD-1 Inhibitors in Small-Cell Lung Cancer

Immunotherapy As a Treatment for Small Cell Lung Cancer: a Case Report and Brief Review

A narrative review of current and potential prognostic biomarkers for immunotherapy in small-cell lung cancer

Immunotherapy for small cell lung cancer: the current state and future trajectories

Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer

Combinational Immunotherapy Based on Immune Checkpoints Inhibitors in Small Cell Lung Cancer: is This the Beginning to Reverse the Refractory Situation?

Prognostic Biomarkers and Immune Cell Infiltration Characteristics in Small Cell Lung Cancer

Advances in new targets for immunotherapy of small cell lung cancer

First-line Sintilimab Combined with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer: A Phase II Study and Post-Hoc Biomarker Analysis.

A New Hope: the Immunotherapy in Small Cell Lung Cancer

Potential biomarkers for immunotherapy in non-small-cell lung cancer

[Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer].

Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients

Therapeutic efficacy analysis of immunotherapy in small cell lung cancer

Predictive biomarkers for immunotherapy response in extensive-stage SCLC

Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers